Sudeep Pharma Ltd (SUDEEPPHRM) Q1 FY27 Results Analysis: PAT Surges 31.6%, EBITDA Margin Misses Target

Sudeep Pharma Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 158.27 Cr (+26.70% YoY) and PAT growth of +31.63% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Strong Q1 with 26.7% revenue growth and 31.6% PAT growth. The Pharma, Food & Nutrition segment beat management's >10% guidance by a wide margin. However, gross margin compression and elevated employee costs kept EBITDA margin below the 37-38% target. The Nandesari Unit IV capex and US tailwinds provide near-term catalysts, but margin recovery is still a work in progress.

Key Investment Insights

Key Positives

• Pharma, Food & Nutrition segment revenue grew 30.64% YoY to Rs.108.41 Cr, exceeding management's >10% full-year guidance.
• Consolidated revenue grew 26.70% YoY to Rs.158.27 Cr.
• PAT attributable to owners grew 31.63% YoY to Rs.40.55 Cr.
• Standalone revenue grew 31.82% YoY, faster than consolidated.
• EBITDA margin improved sequentially from 34.33% to 34.69%.
• Subsidiary contribution to PAT increased to Rs.6.72 Cr from Rs.5.60 Cr a year ago.

Risk Factors

• Gross margin compressed 187 bps YoY to 64.25% due to pass-through of raw material price reductions in contracts.
• Specialty Ingredients EBITDA margin fell to 30.53% from 40.68% a year ago.
• Employee costs spiked 36.31% QoQ, pressuring near-term margins.
• EBITDA margin of 34.69% remains 231-331 bps below the stated target of 37-38%.